Manor Solomon scores again as Fulham reach the last eight with win over Leeds

Reuters

UPDATE 1-U.S. FDA approves Reata’s rare genetic disorder drug

The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc’s drug for the treatment of a rare genetic disorder that causes progressive damage to the nervous system, sending shares up nearly 160% after the bell. The drug, Skyclarys, is Reata’s first product to gain approval, and Jefferies analyst Maury Raycroft projected that U.S. sales of the drug could reach $400 million by 2030. Reata estimates the disorder, called Friedreich’s ataxia, affects about 5,000 patients in the United States.